Efficacy and Safety of Tolvaptan in Cirrhotic Patients With Hyponatremia
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This is a phase IV, open-label, prospective cohort study for 7 days.The recommended starting
dose of tolvaptan is 15 mg daily orally. The dose may be titrated on the next day at 15 mg
intervals up to 60 mg daily according to the serum sodium level response.Serum sodium level,
change in sodium level from baseline, quality of life (EQ-5D-3L), change in body weight,
edema, renal function, mortality and liver-related complications on day 7 and day 30 to
evaluate the efficacy of tolvaptan in cirrhotic patients with hyponatremia.